Virax Biolabs
VRAX
6 hedge funds and large institutions have $141K invested in Virax Biolabs in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
20% more funds holding
Funds holding: 5 → 6 (+1)
0.14% less ownership
Funds ownership: 0.2% → 0.06% (-0.14%)
67% less capital invested
Capital invested by funds: $424K → $141K (-$282K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$33.3K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$22.7K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$19.9K |
| 4 |
Morgan Stanley
New York
|
+$191 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$48 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$282K |
| 2 |
Squarepoint
New York
|
-$78.8K |
| 3 |
Jane Street
New York
|
-$22.6K |
| 4 |
HT
Headlands Technologies
Chicago,
Illinois
|
-$359 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $85.3K | +$33.3K | +696 | +85% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $26.7K | +$22.7K | +475 | New |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $23K | +$19.9K | +416 | New |
|
|
RS
4
R Squared
Central,
Hong Kong
| $6.08K | +$5.17K | +108 | New |
|
|
5
Morgan Stanley
New York
| $225 | +$191 | +4 | New |
|
|
6
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $45 | +$48 | +1 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $20 | – | – | – |
|
|
8
Renaissance Technologies
New York
| – | -$282K | -5,816 | Closed |
|
|
9
Squarepoint
New York
| – | -$78.8K | -1,625 | Closed |
|
|
10
Jane Street
New York
| – | -$22.6K | -465 | Closed |
|
|
HT
11
Headlands Technologies
Chicago,
Illinois
| – | -$359 | -7 | Closed |
|
VRAX Hedge Fund Activity: Q4 2024 in Review
6 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q4 2024, worth a combined $141K — down 67% from $424K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VRAX positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $33.3K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $282K sold.
- 6 institutional investors held Virax Biolabs (VRAX) as of Q4 2024, up from 5 in Q3 2024.
- Funds reported $141K of Virax Biolabs stock for Q4 2024, down 67% quarter-over-quarter.
- 5 funds opened new Virax Biolabs positions in Q4 2024 and 4 closed out, a net change of +1 holder.
- The largest Virax Biolabs buyer in Q4 2024 was UBS Group, an estimated $33.3K added.
- The largest Virax Biolabs seller in Q4 2024 was Renaissance Technologies, an estimated $282K sold.
Based on aggregated 13F filings for Q4 2024.